Note: Ingredients listed on restricted chemical lists
EC/CAS
128-44-9
Name of the chemical
1,2-benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt
Concentration
N/A
EC/CAS
99-76-3
Name of the chemical
4-hydroxybenzoic acid, methyl ester
Concentration
N/A
EC/CAS
94-13-3
Name of the chemical
Propylparaben; propyl 4-hydroxybenzoate
Concentration
N/A
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
1934-21-0
Name of the chemical
Trisodium 5-hydroxy-1-(4-sulphophenyl)-4-(4-sulphophenylazo)pyrazole-3-carboxylate and aluminium lake (17); (CI 19140)
Concentration
N/A
EC/CAS
25956-17-6
Name of the chemical
Disodium 6-hydroxy-5-[(2-methoxy-4-sulphonato-m-tolyl)azo]naphthalene-2-sulphonate (17); (CI 16035)
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Revision date
2015-06-10
Product name
Metoclopramide Oral Solution, USP
Product name
Metoclopramide Oral Solution, USP
Identification on the label/Trade name
None
Chemical name
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide
Manufacturer Name
ANI Pharmaceuticals, Inc
Icons in SDS
Company Information
company name
ANI Pharmaceuticals, Inc
Section 2
SECTION 2: Hazards identification
Emergency Overview The potential for exposure is reduced in finished pharmaceutical form. However, effects of exposure may include high/low blood pressure, irregular heartbeat, allergic reactions, Methemoglobinemia and DNA damage. Signs and symptoms of overexposure include metoclopramide-restlessness, drowsiness, fatigue, weariness, insomnia, headache, confusion, dizziness, mental depression, endocrine disturbances, nausea, bowl disturbances (diarrhea), loss of bladder control, disorientation, muscle spasms, incoordination, rash, welts, difficulty breathing.
